Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 18064037.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A major problem in hepatitis C virus (HCV) immunotherapy or vaccine design is the extreme variability of the virus. We identified human monoclonal antibodies (mAbs) that neutralize genetically diverse HCV isolates and protect against heterologous HCV quasispecies challenge in a human liver-chimeric mouse model. The results provide evidence that broadly neutralizing antibodies to HCV protect against heterologous viral infection and suggest that a prophylactic vaccine against HCV may be achievable.
Medical subject headings
- Hepacivirus
- Hepatitis Antibodies
- Hepatitis C